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Abstract: Alzheimer’s disease is a progressive, incurable, and complex neurode-
generative disease. Currently, an effective treatment that can slow down or stop the 
damage and death of neurons, which is a characteristic of Alzheimer’s disease, is 
lacking. Taking into account the complex nature of the disease, a multitarget design 
approach has been developed for the production of new potential anti-AD agents. 
The goal of this approach is to create a single molecule that can interact selectively 
with several desired molecular targets relevant to the disease. This strategy was suc-
cessfully developed two decades ago and has been improved in recent years. This 
chapter describes the progress made in the discovery and design of selected multi-
targeted drugs based on molecular targets, which can be used for treating 
Alzheimer’s disease. The most promising among these drugs are the molecules 
having properties that are valuable not only in the symptomatic therapy but also in 
the causal treatment of the disease. The main hypotheses of Alzheimer’s disease, 
such as β-amyloid (Aβ), tau, and cholinergic, suggest that compounds capable of 
inhibiting the aggregation of neurotoxic Aβ-amyloid peptide and tau protein, and 
improving the cholinergic neurotransmission, may possess such properties. 
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Examples of such multifunctional molecules, which have been recently reported in 
the literature, are presented in this chapter.
Keywords: Alzheimer’s disease; disease-modifying strategies; multimodal com-
pounds; polypharmacology; symptomatic strategies
INTRODUCTION
Alzheimer’s disease (AD) is a progressive, incurable, and complex neurodegen-
erative disorder. The two main neuropathological hallmarks of AD are extracel-
lular amyloid plaques composed of β-amyloid (Aβ), and intracellular 
neurofibrillary tangles (NFTs) containing the tau protein, leading to nerve cell 
death. In addition, AD is characterized by a low level of the neurotransmitter 
acetylcholine and loss of cholinergic neurons, excitotoxicity, impairment of 
other neurotransmitter systems, extensive oxidative stress, chronic neuroin-
flammation, mitochondrial dysfunction, calcium and metal dyshomeostasis, 
and other factors (1). This complex and unclear pathogenesis of AD has led to 
the creation of several theories. The oldest one is the cholinergic hypothesis, 
followed by others such as the Aβ hypothesis, the tau hypothesis, the oxidative 
stress theory, the metal imbalance theory, the mitochondrial cascade, and the 
inflammation hypothesis were developed. The available AD therapy is based 
only on medications that are capable of treating the cognitive symptoms: three 
cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and one 
N-methyl-d-aspartic acid (NMDA) receptor antagonist (memantine). Currently, 
an effective treatment that may slow down or stop the damage and death of 
neurons in AD is lacking.
Complex diseases such as AD require a more intricate treatment (2, 3), and 
hence, agents acting on only one particular target or modulating only one process 
are not sufficient. This problem can be overcome by two possible approaches. The 
first, polypharmacy, involves combination therapies with the use of two or more 
drugs (4). An alternative way is to use multifunctional compounds that exhibit 
many effects by interacting with more than one biological target (5, 6). Such mol-
ecules, which are referred to as multifunctional or multidirectional compounds, 
multitargeted ligands (MTLs), or multitarget-directed ligands (MTDLs), provide 
additive or synergistic effects, called polypharmacology (7).
The issues related to the use of combination therapies for AD have been 
recently described by Cummings et al. (8). Pharmacodynamic combination thera-
pies are based on two or more symptomatic agents that can improve the behav-
ioral and cognitive symptoms of AD and/or disease-modifying therapies (DMTs) 
that affect the causes of the disease. In 2014, Namzaric, a combination of two 
symptomatic medications—the cholinesterase inhibitor, donepezil and the NMDA 
receptor antagonist, memantine—was approved for the treatment of AD patients 
with moderate-to-severe dementia (9). Currently, various clinical trials are ongo-
ing on combination therapies involving a standard-of-care medication like a cho-
linesterase inhibitor or memantine combined with another agent. Selected add-on 
clinical trials of combination treatment for AD, using a small molecule with a 
standard-of-care medication, are presented in Table 1.
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MULTITARGET LIGANDS APPROACH
Combination therapy has some disadvantages resulting from the possible accu-
mulation of drug side effects, pharmacokinetic complexity, drug–drug interac-
tions, and decreased compliance. Moreover, older patients might feel that using 
one tablet is more convenient than using two or more. Multifunctional com-
pounds are free of the above-mentioned disadvantages. Since these agents can be 
considered as a form of multicomponent therapy, the creation of new molecules is 
based on similar principles. Multifunctional agents can be designed by combing 
two or more structures of active agents or their pharmacophore fragments that 
interact with the desired targets. Possible strategies for designing multifunctional 
agents include combining molecules that can interact with two symptomatic tar-
gets or symptomatic targets and disease-modifying targets or with two disease-
modifying targets. The targets of DMT are neurotoxic aggregates of Aβ and tau 
TABLE 1 Selected add-on clinical trials of combination 
treatment for AD using a small molecule with a 
standard-of-care medication
Agent Biological target Phase Baseline Therapy Clinical trials
Masitinib Selective tyrosine kinase 
inhibitor
III Rivastigmine and/or 
memantine
NCT01872598
Telmisartan Angiotensin II receptor 
antagonist
II AChE inhibitor and/or 
memantine
NCT02085265





II AChE inhibitor and/or 
memantine
NCT02727699
ANAVEX2-73 Sigma-1 chaperone agonist II AChE inhibitor and/or 
memantine
NCT02244541
Neflamapimod P38 MAPK alfa inhibitor II AChE inhibitor or 
memantine
NCT03402659
CT1812 Antagonist of the sigma-2 
receptor
II AChE inhibitor or 
memantine
NCT02907567
Idalopirdine 5-HT6 receptor antagonist III Donepezil or donepezil 
and memantine
NCT01955161
Citalopram Selective serotonin reuptake 
inhibitor
III AChE inhibitor and/or 
memantine
NCT00898807
Rasagiline MAO-B inhibitor II AChE inhibitor or 
memantine
NCT02359552
Piromelatine Melatonin and serotonin 
receptor agonist
II AChE inhibitor or 
memantine
NCT02615002
AD, Alzheimer’s disease; AChE, acetylcholinesterase; MAO, monoamine oxidase; MAPK, mitogen-activated protein 
kinase.
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protein, as well as various processes associated with neuroprotection or neuroin-
flammation. The targets of symptomatic therapy are the cholinergic system, 
including acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) 
enzymes, NMDA neurotransmission, G protein-coupled receptors (GPCRs), and 
monoamine oxidase (MAO) enzymes (Table 2).
A multitarget design approach was successfully developed two decades ago 
and has been improved in recent years. There are basically three ways to combine 
pharmacophores to form an MTL structure, which can interact with appropriate 
biological targets (10). The simplest way is to connect two pharmacophores 
through a linker. Another way is to combine two pharmacophore fragments with-
out a linker, forming condensed molecules. The third and best way is to create 
merged pharmacophores that result in small molecules with low molecular weight 
and thus with good drug-like properties. Over the years, various potential multi-
functional anti-AD agents have been designed, synthesized, and developed 
(11–13). Based on the structures of currently used anti-AD drugs or their 
TABLE 2 Therapeutic strategies of AD applied for the 
creation of multifunctional agents
Therapeutic strategies 
for AD treatment Target for AD treatment Agents
Disease modifying therapies Aβ aggregates β-Secretase inhibitor
Aβ aggregation inhibitor
Metal chelator










Symptomatic therapies Cholinergic neurotransmission AChE inhibitor
BuChE inhibitor














Oxidative damage MAO-A inhibitor
MAO-B inhibitor
AD, Alzheimer’s disease; AChE, acetylcholinesterase; BuChE, butyrylcholinesterase; COX, cyclooxygenase; FAAH, fatty 
acid amide hydrolase; GPCR, G protein-coupled receptors; GSK, glycogen synthase kinase; LOX, lypoxygenase; MAO, 
monoamine oxidase; NMDA, N-methyl-d-aspartic acid; PDE4, phosphodiesterase 4.
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pharmacophoric fragments, multimodal compounds are produced. Thus, ligands 
containing fragments of tacrine (as a strong inhibitor of cholinesterases), donepe-
zil, or rivastigmine are the most numerous. Of these, only ladostigil has entered 
phase II/III clinical trials in patients with mild cognitive impairment. Its structure 
represents a merged pharmacophore, which is formed by combining a propargyl-
amine moiety derived from an MAO-A/B inhibitor rasagiline with a pharmacoph-
oric carbamyl moiety derived from rivastigmine. Ladostigil is a dual AChE/BuChE 
and a brain-selective MAO-A/B inhibitor possessing in vivo neuroprotective prop-
erties (14) and, as such, is an example of a multifunctional agent created by com-
bining two pharmacophores that act on the symptomatic targets of AD.
Among the various multifunctional agents, the largest group that focuses on 
the targets of symptomatic therapy is cholinesterase inhibitors combined with 
other targets (15). Dual binding site cholinesterase inhibitors capable of interact-
ing with the catalytic active site and the peripheral anionic binding site of AChE 
can inhibit Aβ aggregation. Based on this action, many such ligands were obtained, 
which showed potency toward both symptomatic targets (AChE/BuChE) and dis-
ease-modifying targets (Aβ aggregation) (16–20). Herein, the recent advances 
made in the design of multifunctional agents for AD treatment based on molecular 
targets and selected examples of novel multimodal ligands are presented.
MULTIFUNCTIONAL AGENTS FOCUSING ON DISEASE-
MODIFYING TARGETS: Aβ AND OTHERS
The Aβ hypothesis assumes that the primary cause of neuron loss is the formation 
of senile plaques due to abnormal processing of amyloid precursor protein (APP) 
(21). The key role in this process is played by the β-secretase enzyme (BACE-1, 
Aβ precursor protein-cleaving enzyme 1), which together with γ-secretase cleaves 
APP, producing Aβ peptides consisting of 38–42 amino acids. Because of their 
fibrillogenic and hydrophobic nature, Aβ peptides accumulate easily. These pep-
tide aggregates induce oxidative stress, neuroinflammation, hyperphosphoryla-
tion, and the aggregation of tau protein, ultimately resulting in loss of neurons 
and dementia. Based on this theory, some biological disease-modifying targets 
have been identified and are used in the search for new anti-AD agents. Inhibition 
of BACE-1 and amyloid aggregation is considered as the most important objective 
of these agents. Currently, 38 (29%) Aβ-targeting agents are undergoing clinical 
trials, of which four BACE-1 inhibitors are gaining continued interest as biological 
targets in the field of drug discovery and development (22). BACE-1 inhibition 
has also been applied for the generation of MTDLs having other beneficial 
properties.
BACE-1 inhibitors with other properties
The structure of donepezil is widely used as a pharmacophoric moiety for devel-
oping multifunctional agents (19). Examples of compounds formed using the 
donepezil structure are N-benzylpiperidine analogs acting as BACE-1 and AChE 
inhibitors with antioxidant and antiaggregating properties, which were described 
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by Sharma et al. (23). As a core group, N-benzylpiperidine moiety present in 
donepezil and capable of inhibiting BACE-1 was selected. Virtual screening led to 
the emergence of the hit compound SEW06622. Based on its structure, a series of 
new anti-AD agents was designed. The compounds differed in the substitution of 
benzylamine and the presence of a double bond close to the nitrogen atom. The 
design of these compounds is presented in Figure 1. Among them, compound 1 
Figure 1. Multifunctional agents focusing on disease-modifying targets: BACE-1, Aβ, and others.
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was found to be the most promising. Besides inhibiting both BACE-1 and AChE 
enzymes with IC50 values in the submicromolar range, it showed blood–brain 
barrier (BBB) permeability in the parallel artificial membrane permeability assay 
(PAMPA) and inhibited self-induced and AChE-induced Aβ aggregation, while 
proving to be safe in SH-SY5Y neuroblastoma cell lines at a concentration of up to 
80 μM. Most importantly, it alleviated cognitive impairment in rat models of 
 scopolamine-induced amnesia and by continuous intracerebroventricular infu-
sion of a pathogenic dose of Aβ peptides. In addition, compound 1 displayed 
good pharmacokinetic parameters after oral administration. Therefore, it can be 
considered as a potential drug candidate for AD treatment (23).
The approach to obtain disease-modifying and symptomatic multifunctional 
ligands inspired the design and synthesis of a group of 1-benzylamino-2- 
hydroxyalkyl derivatives (24). The new multifunctional agents contained substi-
tuted benzylamine, responsible for inhibiting BuChE, connected to aromatic 
fragments: benzyl, phenyl, and benzhydryl through a 2-hydroxyethyleneamine 
linker. This linker was suggested to confer the agents with BACE-1 inhibitory 
activity. Among these ligands, the diphenylpropylamine derivative 2 (Figure 1) 
was the most interesting, which was capable of inhibiting BACE-1 and BuChE, as 
well as Aβ and tau aggregation. Due to its broad biological profile, it is regarded 
as a potential multifunctional compound (24).
Multifunctional agents combining Aβ antiaggregation effects with 
other activities
A series of tetrahydroisoquinoline–benzimidazole derivatives was developed, which 
represent multifunctional anti-AD agents focusing only on the disease-modifying 
effects (25). To design this group, two well-known pharmacophores, benzimid-
azole, present in BACE-1 and inflammation inhibitors, and a tetrahydroisoquino-
line moiety possessing anti-inflammatory, antioxidation, and neuroprotection 
properties, were chosen. Benzene or pyridine ring was used as a linker. Among 
the obtained derivatives, compound 3 showed the most balanced profile 
(Figure 1). It inhibited nitric oxide (NO) production in lipopolysaccharide (LPS)-
induced BV2 microglia cells with an IC50 value of 5.07 µM and BACE-1 activity 
by 65.7% at a concentration of 20 µM. Additionally, it showed a strong neuropro-
tective effect against glutamate-induced cell death at 5 µM (91.8% cell viability) 
and reduced the level of proinflammatory cytokines such as TNF-α and IL-1β. 
Furthermore, the ability to penetrate the BBB demonstrated that compound 3 is a 
promising multiple anti-AD ligand.
Suppressing the formation of senile plaques is feasible not only by the inhibi-
tion of enzymes involved in the pathological Aβ cascade but also by direct inhibi-
tion of Aβ aggregation. Kong’s group (26) designed compounds that displayed 
this property as well as other anti-AD activities, based on two structures: donepe-
zil and Trolox, an antioxidative analog of vitamin E. The Trolox fragment was 
fused with a differently substituted N-benzylpiperidine moiety derived from 
donepezil by an amide bond. The designed compounds were supposed to bind to 
both active sites of AChE and inhibit AChE, Aβ aggregation, and MAOs, while 
also acting as antioxidants. The biological evaluation of the effect of these com-
pounds on all proposed targets revealed that compound 4, which had a fluor 
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atom in position 2 of benzene ring, was a promising MTDL (Figure 1). This com-
pound inhibited both cholinesterases (IC50 hAChE = 0.54 µM, IC50 hBuChE = 
5.97 µM). Moreover, it displayed nonselective inhibitory activity against MAO-A 
and MAO-B at a micromolar range. Its antioxidant property compared to Trolox 
was confirmed in three different experiments. Furthermore, compound 4 exhib-
ited a metal-chelating effect, especially with copper ions, which are associated 
with AD pathogenesis. The results of self-induced and metal-induced Aβ aggrega-
tion assays also indicated that compound 4 can inhibit both types of Aβ aggrega-
tion. The promising outcomes of the in vitro assays were translated successfully to 
in vivo experiments, in which multifunctional ligand 4 was found to significantly 
improve cognitive decline in scopolamine-, d-galactose-, and AlCl3-induced 
memory deficit models. All these results suggested that this compound is an 
excellent anti-AD candidate.
Another antioxidant and antiaggregating molecule that can serve as a multi-
functional compound is the well-known natural derivative resveratrol. For design-
ing new hybrid structures, deferiprone, metal-chelating drug was used (27). These 
two structures were merged by replacing one of the aromatic rings of resveratrol 
by deferiprone moiety (Figure 1). Among the newly synthesized hybrids, com-
pound 5 possessing an ethoxy group at position 4 showed triple anti-AD func-
tions—inhibition of Aβ aggregation, antioxidation, and metal chelation. Such 
properties make it a potential disease-modifying drug candidate.
MULTIFUNCTIONAL AGENTS FOCUSING ON DISEASE-
MODIFYING TARGETS: TAU PROTEIN AND OTHERS
Besides the presence of senile plaques in the brain of patients suffering from AD, 
the occurrence of NFTs consisting of hyperphosphorylated tau protein aggregates 
is discerned as the second hallmark of the disease. Based on this observation, the 
tau hypothesis was formulated to explain the development of AD (28). Tau is a 
microtubule-associated protein, which, in the physiological condition, stabilizes 
the microtubules and takes part in axonal transport. During the pathological 
 process, kinases, especially glycogen synthase kinase (GSK-3β) and GSK-3α, 
excessively phosphorylate this protein, resulting in a loss of function. 
Hyperphosphorylated tau proteins aggregate and easily create intracellular 
lesions—primarily paired helical filaments and further NFTs. As indicated by the 
tau theory, the presence of these aggregates contributes to all the processes related 
to the AD pathomechanism leading to dementia, including Aβ aggregation. 
Therefore, in drug discovery and development, the tau-centered approaches, 
which involve the interaction with kinases, mainly the GSK-3β enzyme, and the 
direct inhibition of tau aggregation process, are especially important (29).
Tau and Aβ inhibitors
One of the valuable strategies applied in the search of new anti-AD agents is the 
dual inhibition of Aβ and tau aggregation for reducing simultaneously the level of 
both lesions. An example of these agents is 1,2,3,4-tetrahydro-1-acridone 
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analogs, which were designed by combining the structure of tacrine with quino-
lone moiety, and the antiaggregating compound cinnamaldehyde containing 
α, β-unsaturated carbonyl fragment (30). Among the derivatives that differed in 
the length of linker, degree of saturation, substitution of cinnamaldehyde moiety, 
and methylation of the nitrogen atom of tacrine, five compounds inhibited Aβ1–42 
and tau aggregation by 84.7–99.5% and 71.2–101.8%, respectively, at the 
 screening concentration of 20 μM. All these compounds had a quaternary amine 
considered crucial for the observed inhibitory activities. Compound 6 with a 
naphthalene residue (Figure 2), which was identified as a noncovalent inhibitor 
of both neurotoxic proteins and predicted to penetrate the BBB as well as prevent 
tau aggregation in living cells, was selected as the most promising dual agent.
Due to its rich biological properties, the curcumin scaffold is highly preferred 
in the design of multiple antiaggregation agents. It is a natural polyphenol, 
reported to have antioxidant, antiaggregating, and anti-inflammatory activities, 
and is used as a yellow spice. Because of its poor pharmacokinetic parameters, 
especially bioavailability, the scaffold is not applied in the treatment of AD. 
However, its structure was included in a series of potential multifunctional ligands 
(31). Compound 7 (PE859) is a perfect example of such ligands (32) (Figure 2), 
which was found to display higher dual antiaggregating properties compared to 
the parent compound. Moreover, it penetrated the BBB, improved memory in vivo, 
reduced the amount of both aggregated lesions in mice brains, and showed a 
promising pharmacokinetic profile.
Dual Aβ and tau antiaggregating properties were also combined with anticho-
linesterase activity in order to achieve disease-modifying and symptomatic effects. 
However, it should be noted that such hybrid molecules were designed as dual 
binding site cholinesterase inhibitors with potential Aβ antiaggregating proper-
ties. The hybrids described by Muñoz-Torreo et al. (33) were formed by the fusion 
of 6-chlorotacrine, a strong AChE inhibitor, and the previously described tetrahy-
drobenzonaphthyridine derivatives capable of interacting with both active sites of 
AChE and displaying weak Aβ aggregation inhibitory activity. This combination 
allowed obtaining a group of compounds that can target tau, Aβ, and cholinester-
ases. The most potent derivative 8 (Figure 2) inhibited hAChE with an IC50 value 
of 2.06 nM and hBuChE with 0.286 μM, as well as Aβ42 and tau aggregation by 
77.5% and 68.7%, respectively, in recombinant Escherichia coli cells at a concen-
tration of 10 μM. However, a major disadvantage of this compound is its weak 
drug-likeness. Similarly, a series of shogaol–huprine hybrids displaying antioxi-
dant properties, in addition to anticholinesterase and antiaggregating activities, 
was developed, which was characterized by poor drug-likeness (34).
GSK-3β inhibitors with other activities
The inhibition of tau protein phosphorylation by interaction with GSK-3β is an 
important tau-centered approach. A group of researchers from the University of 
Bologna (35) developed a series of 2,4-thiazolidinedione derivatives, which were 
capable of inhibiting not only GSK-3β but also directly the tau aggregation pro-
cess. Compound 9 possessing a substituted indole moiety (Figure 2) was the most 
potent GSK-3β inhibitor (IC50 = 0.89 μM). It inhibited the AcPHF6 aggregation 
peptide (306VQIVYK311) up to 80% in a model system at 10 μM concentration. 
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Figure 2. Structures of small molecules targeting tau protein and other targets.
Multifunctional Ligand Approach 191
The BBB permeability of the derivatives revealed by PAMPA, their safety, and abil-
ity to inhibit truncated and full-length tau aggregation allow regarding them as 
tau-centric multitarget agents.
A new disease-modifying strategy that suppressed both amyloid and tau cas-
cades by the inhibition of two enzymes, GSK-3β and BACE-1, was proposed by 
Bolognesi’s group (36, 37). A series of triazinones was designed based on two 
fragments: a guanidine motif interacting with BACE-1 and a cyclic amide group 
binding to GSK-3β. Among the obtained derivatives, compound 10 (Figure 2) 
was recognized as a novel well-balanced multiple anti-AD agent (IC50 GSK-3β = 
7.11 μM, IC50 BACE-1 = 16.05 μM) because it showed neuroprotective and neu-
rogenic effects and a good ADME (Adsorption, Distribution, Metabolism, 
Excretion) profile. Thus, it seems to be a promising lead structure for further 
development.
The inhibitory activity against GSK-3β, together with AChE inhibition, was 
proposed as a new strategy by Chinese researchers (38). Figure 2 presents the 
most interesting example (compound 11) for simple combination of tacrine scaf-
fold with the structure of a selective GSK-3β inhibitor using an alkyl linker. 
Among the ligands developed by the above team, compound 11 exhibited a 
well-balanced biological profile with the IC50 values in the nanomolar range 
(IC50 hAChE = 6.5 nM, IC50 hGSK-3β = 66 nM). The efficacy of this dual strategy 
was verified in the animal model where compound 11 ameliorated the cognitive 
decline. Moreover, the examined compound did not demonstrate any hepatotox-
icity for tacrine.
Oukoloff et al. (39) also used the same AChE inhibitor fragment for creating 
hybrids, which showed a similar mechanism of action. They connected tacrine 
pharmacophore by a linker containing 1,2,3-triazole with the structure of the 
GSK-3α/β inhibitor valmerin. The in vitro results revealed that compound 12 in 
the form of an R enantiomer (Figure 2) was the most potent, which exhibited 
inhibitory potential with an IC50 value of 9.5 and 7 nM for AChE and GSK-3α/β, 
respectively. Additional advantages of the developed novel tacrine–valmerin mul-
tifunctional ligands were low cytotoxicity and good BBB permeability.
The metal hypothesis of AD indicates that excess levels and dysregulation of 
biometal ions, such as Cu2+, Fe2+, Zn2+, and Ca2+, in the brain cause Aβ aggrega-
tion, generation of reactive oxygen species (ROS), and oxidative stress, leading to 
cell death (40). Metal chelators are potential anti-AD agents and are also used in 
the development of multifunctional agents (41). A novel approach based on 
combing GSK-3β inhibitors with agents exhibiting metal-chelating and 
Aβ-antiaggregating properties was recently presented. The newly formed com-
pounds included 2,3-diaminopyridine derivatives (42) and hydroxy-substituted 
trans-cinnamoyl derivatives (43). The most promising representative compound 
13 from the first group (Figure 2) inhibited the GSK-3β enzyme with an IC50 
value of 49 nM and acted as a selective Cu2+ and Al3+ chelator, showing antioxi-
dant and Aβ-antiaggregating properties. On the other hand, compound 14 from 
the second series (Figure 2) exhibited lower inhibitory potency against GSK-3β 
(IC50 = 24.36 µM), but displayed a broad profile of anti-AD activities.
In turn, two series of compounds, benzoxazinone and indole derivatives, were 
designed as dual kinase inhibitors (44). Besides inhibiting GSK-3β, they targeted 
human adenosine kinase (hAK), which also induces the development of AD by 
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regulating the level of adenosine and cytoprotective effects. Based on three well-
known hAK/hGSK-3β inhibitors, the structures of novel agents were designed and 
developed. Among them, 15 (Figure 2) displayed dual kinase inhibitory activity 
(IC50 hAK = 13.6 µM, IC50 hGSK-3β = 6.4 µM) with antioxidant and neuroprotec-
tive properties, and thus identified as an appropriate lead structure for the devel-
opment of multifunctional ligands that can exhibit an innovative mechanism of 
action.
MULTIFUNCTIONAL AGENTS FOCUSING ON SYMPTOMATIC 
THERAPIES WITH ADDITIONAL BENEFICIAL PROPERTIES
In the course of Alzheimer’s disease, it is important to both treat the causes and 
symptoms of the disease. Dementia changes in patients are also associated with 
other disease symptoms, such as depression, anxiety, psychosis, and personality 
changes. According to the oldest theory of AD, dementia changes and memory 
disturbances are associated with damage to cholinergic neurotransmission. Other 
symptoms result from disturbances in other neurotransmitter systems, including 
GPCRs, such as serotonin, H3 histamine receptors, and the cannabinoid system or 
with impaired functioning of enzymatic systems such as MAOs. Hence, the design 
of multifunctional molecules aimed at the treatment of disease symptoms is based 
on combining the inhibitory activity of cholinesterase with the influence on the 
other molecular targets mentioned earlier.
Multifunctional ligands influencing serotonin and cholinergic 
neurotransmission
Among all GPCRs, serotoninergic receptors are the most attractive as they are 
targeted for designing MTDLs as potential treatment of AD. Their particularly 
desired actions are the activation of 5-HT4 receptors (5-HT4Rs) and inhibition of 
5-HT6 receptors (5-HT6Rs) (45). The first action leads to the modulation of APP 
metabolism and redirects the protein to a nonamyloid pathway. In turn, 5-HT6 
blockage improves cognitive performance by increasing the release of glutamate, 
acetylcholine, and catecholamine in the cortical and limbic areas.
The first class of multifunctional ligands formed by combining 5-HT4Rs with 
cholinesterases was presented by Dallemagne’s research team (46). They described 
a compound named donecopride (compound 16, Figure 3) as a new preclinical 
multifunctional drug candidate showing both in vitro AChE inhibitory activity and 
5-HT4R agonistic potency. Moreover, donecopride also displayed in vivo procogni-
tive and antiamnestic activities in mice. The same research group (47) described 
novel MTLs with an interesting biological profile, which were capable of restoring 
cholinergic transmission through the activation of 5-HT4R, blockage of 5-HT6R, 
and inhibition of AChE. This class of compounds was developed by merging the 
previously developed dual compound with the benzyl analog of donecopride dis-
playing in vitro 5-HT4R agonist and 5-HT6R antagonist properties. The most inter-
esting compound was 17 (Figure 3), a fumaric acid salt exhibiting well-balanced 
activities toward all the three mentioned targets. Compound 17 was found to act 
Multifunctional Ligand Approach 193
as a partial agonist of h5-HT4R (Ki = 210 nM), an inverse agonist of h5-HT6R (Ki 
= 219 nM), and an inhibitor of hAChE (IC50 = 33.7 nM). Additionally, the com-
pound was tested in vivo in a model of scopolamine-induced working memory 
deficit, where it displayed antiamnestic effects at a dose of 0.3 mg/kg.
Several multifunctional ligands based on the combination of pharmacophores 
that are dedicated to 5-HT6R blockage and cholinesterase inhibition were devel-
oped by Więckowska et al. (48, 49). These novel hybrid ligands were obtained by 
combining the pharmacophores directed against 5-HT6R (1-(phenylsulfonyl)-4-
(piperazin-1-yl)-1H-indole) and cholinesterases (tacrine or N-benzylpiperidine 
analogs). Among them, compound 18 (Figure 3) was the most interesting as it 
displayed potent and balanced antagonist activity toward 5-HT6R (Ki = 27 nM) 
and inhibitory effect against both cholinesterases (IC50 AChE = 12 nM, IC50 
Figure 3. Multifunctional ligands influencing serotonin or histaminergic neurotransmission and 
cholinesterases.
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BuChE = 29 nM). The compound also showed good in vitro BBB permeability 
(proved by PAMPA). Additionally, an in vivo study with the use of a scopolamine-
induced hyperlocomotion rat model confirmed the central cholinomimetic activ-
ity of the compound (48). The further development of this series of hybrids 
resulted in multifunctional ligands with Aβ antiaggregation properties (49).
Indole-based multifunctional ligands were designed, synthesized, and evalu-
ated for the treatment of AD as 5-HT6R blockers with inhibitory abilities toward 
eqBuChE and antioxidant properties (50). Based on the biological screening of the 
5-HT6R antagonists against BuChE, two compounds were selected. In order to 
improve their BuChE inhibitory activity, structural modifications were introduced 
in the next stage in the two series of compounds. Of them, ligand 19 (Figure 3) 
displayed beneficial, dual activity targeting 5-HT6R (Ki = 41.8 nM) and eqBuChE 
(IC50 = 5.07 μM), in addition to favorable antioxidant properties that were com-
parable with the reference ascorbic acid.
Multifunctional ligands combining H3R antagonism and 
cholinesterase inhibition
Histamine H3 receptor (H3R) belongs to the GPCRs family. In the central nervous 
system (CNS), H3R acts as a presynaptic autoreceptor and is involved in inhibiting 
the release of histamine and the modulation of other neurotransmitters such as 
acetylcholine. Numerous in vivo studies have proven that both antagonist and 
inverse agonists of H3R improve cognitive deficits, memory, and spatial orienta-
tion (51). Based on their results, H3R is frequently chosen as a biological target for 
anti-AD multifunctional ligands (52–54).
An international multiteam group discovered new multifunctional ligands with 
a broad and well-balanced spectrum of activities against H3R, AChE, BuChE, and 
MAO-A/B (55, 56). These new indole derivatives were designed by combining the 
neuroprotectant ASS234 with cholinesterase- and MAO-inhibiting motifs and cip-
roxifan containing H3R-blocking and MAO-inhibiting pharmacophore fragments 
(Figure 3). Among the newly formed hybrids, contilisant was identified as the most 
promising multifunctional agent. It inhibited hMAO-A (IC50 = 1.85 μM, after 30 
min of preincubation IC50 = 0.145 μM), hMAO-B (IC50 = 1.94 μM, after 30 min of 
preincubation IC50 = 0.078 μM), hAChE (IC50 = 0.530 μM), and hBuChE (IC50 = 
1.690 μM), as well as blocked H3R (Ki = 10.8 nM). Moreover, contilisant demon-
strated in vitro antioxidant neuroprotective effects and the ability to penetrate the 
BBB in PAMPA. Due to its original in vitro biological profile, contilisant was selected 
for in vivo studies and tested using the novel object recognition test in mice with 
LPS-induced cognitive deficit. Based on the excellent in vitro data supported by 
positive in vivo activity, contilisant was studied further with the aim of exploring new 
pharmacological properties that may be potentially beneficial for AD therapy (57). 
The studies revealed another valuable activity of the compound: selective agonistic 
effect on Sigma 1 receptor (S1R) (Ki = 65.2 nM). S1R is associated with learning and 
memory processes, and hence, its agonists are used as antiamnestic agents in a vari-
ety of pharmacological models, probably due to the improvement of glutamatergic 
and cholinergic neurotransmissions. Additional in vivo studies including Y-maze 
and radical arm-maze tasks in mice with cognitive impairment induced by Aβ1–42 
oligomers showed that contilisant exhibited higher activity in comparison with the 
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commonly used anti-AD drug donepezil. Due to its multifunctional profile as well 
as in vitro activities, which were reflected in in vivo tests, contilisant thus seems to 
be  an interesting multifunctional ligand for further development as a disease- 
modifying anti-AD agent (57).
A number of anti-AD multifunctional ligands have been developed based on 
naturally occurring substances. Wang et al. (58) synthesized a series of multifunc-
tional ligands based on isoflavone, which was recently proven to exhibit inhibi-
tory properties toward cholinesterases. In vitro studies revealed that some of these 
ligands showed a multifunctional profile including blockage of H3R, neuroprotec-
tive effect, and antineuroinflammatory properties. Among them, compound 
20 (Figure 3) is noteworthy since it displayed moderate H3R antagonist property 
(Ki = 270 nM) and potently inhibited AChE (IC50 = 80 nM). In addition, the com-
pound 20 demonstrated neuroprotective and antineuroinflammatory properties. 
The in vivo study also confirmed that it did not induce acute toxicity even at high 
doses (1000 mg/kg), but penetrated through the BBB into the CNS and caused 
significant improvements in mice with scopolamine-induced cognitive deficit, 
which were revealed by passive avoidance test (58).
Ismaili et al. (59) described new small molecules combining activities against 
three biological targets including hH3R. The most promising lead showed high affin-
ity toward hH3R (Ki = 0.565 μM), Ca2+ channel blockade activity (IC50 = 21 μM), 
and moderate selective hBuChE inhibition (IC50 = 7.83 μM), besides strong antioxi-
dant properties and ability to restore cognitive impairment induced by LPS.
Multifunctional ligands targeting endocannabinoid system and 
cholinesterases
Since the discovery that the activation of cannabinoid receptors (CB1R, CB2R) 
causes a reduction in the production of neurotoxic factors (ROS, proinflammatory 
mediators) leading to decreased neuroinflammatory processes, the receptors were 
considered as another biological target in the search for anti-AD agents as well as 
multipotent ligands (60, 61). Consequently, Decker’s group (62) developed a 
series of benzimidazole-based dual-acting ligands that can activate CB2R and 
inhibit BuChE. Among them, the authors highlighted compound 21 as the most 
promising hybrid (Figure 4) as it activated hCB2R with an IC50 value of 0.763 μM 
and hBuChE with an IC50 value of 1.6 μM. It is worth noting that this compound 
21 was selective over hCB1R and AChE. Compound 21 was further evaluated 
in  vivo which revealed that it improved cognitive functions in mice showing 
 neuroinflammation and cognition deficits after Aβ25–35 administration at doses 
ranging from 1 to 3 mg/kg.
In turn, Montanari et al. (63) synthesized multifunctional ligands that indi-
rectly enhanced endocannabinoid signaling by inhibiting fatty acid amide hydro-
lase (FAAH), an enzyme responsible for the degradation of crucial endocannabinoid 
signaling molecules: N-arachidonoylethanoloamine and 2-arachidonoyl glycerol. 
In addition to FAAH, the compounds inhibited cholinesterases. Some of the com-
pounds exhibited very high potencies toward single targets; however, the most 
interesting MTL was compound 22 (Figure 4). It potently inhibited FAAH (IC50 = 
157.2 nM, after preincubation IC50 = 27.9 nM), hAChE (IC50 = 922 nM), and 
hBuChE (IC50 = 42.7 nM).
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Enzyme inhibitors—MAO-A/B and cholinoesterases
MAOs (MAO-A and MAO-B) are the enzymes responsible for the degradation and 
inactivation of monoamine neurotransmitters. The inhibition of MAOs leads to neu-
roprotective effects, not only due to an increase in monoaminergic neurotransmis-
sion but also due to limitations in the production of neurotoxic substances, which 
are by-products of a reaction catalyzed by these enzymes. Due to its multiactive 
nature, the chromone scaffold is commonly applied as a structural motive in the 
development of multimodal ligands. Based on its structure, Reis et al. (64) reported 
a series of dual MAO and cholinesterase inhibitors. Among the tested compounds, 
the most promising was found to be compound 23 (Figure 4), which selectively 
inhibited hAChE (IC50 = 210 nM) over BuChE and nonselectively inhibited both the 
isoforms of MAO (IC50 MAO-A = 0.94 µM, IC50 MAO-B = 3.81 µM). Moreover, the 
additional pharmacokinetic and toxicological studies of compound 23 showed its 
lack of cytotoxicity at a concentration below 25 µM, and PAMPA predicted its 
penetration through the BBB. Thus, the established well-balanced activities, low 
toxicity, and predicted permeability of the tested compound make them interest-
ing multifunctional ligands for AD therapy.
Another group of dual inhibitors of MAOs and cholinesterases was developed 
by connecting N-benzylpiperidine fragment derived from donepezil with 
di- tert-butylated hydroxytoluene, which is a fragment responsible for antioxidant, 
anticancer, and anti-inflammatory properties in numerous compounds (65). These 
inhibitors were analyzed by studies divided into two parts: the first aimed to find an 
appropriate linker to connect the two pharmacophores and the second aimed to deco-
rate the  aromatic ring of the benzylpiperidine scaffold. Among the tested compounds, 
24 was recognized as a double AChE (IC50 eeAChE = 75 nM, IC50 hAChE = 750 nM) 
and MAO-B (IC50 = 7.5 µM) inhibitor with noticeable antioxidant properties and 
 ability to reduce both self-induced and hAChE-induced Aβ aggregation (65).
MULTIFUNCTIONAL AGENTS FOCUSING ON VARIOUS 
DISEASE-MODIFYING AND SYMPTOMATIC THERAPIES
The complexity of AD etiopathogenesis forced a search for new biological targets 
in the CNS and even beyond. Among the numerous molecular targets discovered, 
some have been used to create multifunctional ligands.
In pathological conditions, S1R modulates regulatory proteins, restores cal-
cium homeostasis, and controls the production of ROS, thereby contributing to 
the overall neuroprotection effect (66). Based on their previous study, Rui et al. 
(67) developed multifunctional agents capable of modulating S1R and inhibiting 
AChE. The chemical structure of the new multifunctional ligands was developed 
through an interesting combination of RRC-33 (S1R agonist), curcumin (having 
antioxidant properties), and donepezil. The newly developed compounds exhib-
ited a high affinity to S1R, but very weak AChE inhibitory properties. Among 
them, compound 25 (Figure 4) showed binding affinity to S1R with a Ki value of 
15 nM; however, it inhibited AChE only by 64.80% at a concentration of 50 µM. 
Its neuroprotective effect associated with S1R modulation was confirmed by the 
neurite outgrowth observed in the dorsal root ganglia in the in vitro model (67).
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Interesting biological activities were also presented by flurbiprofen–clioquinol 
hybrids (68). Flurbiprofen is a known potent nonsteroidal anti-inflammatory 
drug, which also inhibits platelet aggregation and Aβ aggregation and reduces tau 
phosphorylation. On the other hand, clioquinol is a metal chelator with proven 
antioxidant properties. Among the obtained hybrids, compound 26 (Figure 4) 
was able to inhibit both self-induced and Cu2+-induced Aβ aggregation and 
MAO-B. In addition, it presented biometal-chelating abilities as well as antioxi-
dant and antineuroinflammatory activities and appropriate BBB permeability.
In turn, Hu et al. (69) developed a novel group of multifunctional compounds 
by combining clioquinol with rolipram or roflumilast. These compounds inhib-
ited phosphodiesterase 4D (PDE4D), an enzyme participating in the process of 
memory consolidation and long-term potentiation. The most interesting of them 
Figure 4. Multifunctional agents focusing on various targets.
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was compound 27 (Figure 4), which inhibited not only the PDE4D with an 
IC50 value of 0.399 µM but also the metal-induced aggregation of Aβ, chelated 
metal ions, and exhibited antioxidant properties (ORAC [oxygen radical absor-
bance capacity] = 0.60 Trolox eq.). In addition to in vitro activity, compound 27 
showed in vivo activity by demonstrating procognitive effects in the Morris 
water-maze test.
Another example of multifunctional compounds is hybrids formed by the 
combination of pharmacophore cyclooxygenase-2 and 15-lipoxygenase enzymes 
with the structure of tacrine (70). These compounds are endowed with antineu-
roinflammatory and anticholinesterase activities.
CONCLUSION
The lack of an effective treatment or DMT capable of influencing the causes of 
AD has led to a constant need to search for new solutions and drugs. Undoubtedly, 
an important issue here is the identification of new disease biomarkers, which 
can indicate early enough the pathological changes in the brain that may lead to 
irreversible processes and symptoms over time. The search for new anti-AD 
agents is challenging due to the complexity of the disease and the corresponding 
lack of appropriate animal models useful in preclinical studies. In addition, 
there is a need for properly planned clinical trials to demonstrate the effective-
ness of the drugs. These problems concern small molecules targeting single 
biological target as well as combination treatment and multifunctional com-
pounds. The clinical trials of combination therapy for AD focus on combining a 
cholinesterase inhibitor or memantine with other medications having various 
therapeutic indications. In this context, multifunctional ligands seem to be a 
much better strategy as they combine effects aimed at both causal and symp-
tomatic treatment of the disease.
The examples presented in this chapter show that the search for new anti-AD 
drugs is based on the combination of pharmacophores acting not only on cholin-
esterases and Aβ aggregation but also on tau protein aggregation (GSK-3β inhibi-
tors), neuroinflammation, and antioxidation. The ligands that regulate the 
influence on GPCRs or MAOs are particularly interesting, taking into account that 
the symptoms of depression or other mental disorders often coexist in AD. This 
may indicate that the proper design of a multifunctional molecule can facilitate 
the discovery of an effective therapy for this devastating disease.
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